PFS With Ibrutinib Combo is ‘Promising’ in Chronic Lymphocytic Leukemia

News
Video

Ibrutinib plus venetoclax appears to be effective across the overall chronic lymphocytic leukemia population in the CAPTIVATE study, although progression-free survival is shorter for those with TP53 mutations.

During the 2023 American Society of Hematology (ASH) Annual Meeting, Paolo Ghia, MD, PhD, spoke with CancerNetwork® about how combining ibrutinib (Imbruvica) with venetoclax (Venclexta) yielded positive progression-free survival (PFS) data in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma based on up to 5 years of follow-up data from the phase 2 CAPTIVATE study.

According to Ghia, a full professor in Medical Oncology at Università Vita-Salute San Raffaele, and the deputy chairman of the Division of Experimental Oncology at IRCCS Ospedale San Raffaele, Milano, fixed-duration therapy with ibrutinib plus venetoclax appeared to be effective across the general study population. However, the PFS rate was lower for those with TP53-mutated disease; he suggested that further follow up may be necessary for this patient subgroup.

The 54-month PFS rate was 70% (95% CI, 62%-77%) in the fixed-duration cohort (n = 159) and 45% (95% CI, 25%-64%) in those with a TP53 mutation or 17p deletion (n = 27). Additionally, investigators reported corresponding rates of 68% (95% CI, 50%-80%) in patients with unmutated IGHV (n = 40), 64% (95% CI, 30%-85%) in those with an 11q deletion (n = 11), and 60% (95% CI, 41%-75%) in a group of patients with complex karyotype.

Transcript:

We also presented the data about progression-free survival. Now, of course, we all want to know how long patients remain off therapy and whether they [will] progress. After a fixed-duration treatment and 54 months of follow up, 70% of the patients are still responding; patients with unmutated [IGHV], 68% are still responding. Patients with TP53 aberrations are losing a little bit of response earlier; still, 45% of them are responding after 54 months of follow up.

These are very promising data. The fixed-duration treatment with ibrutinib plus venetoclax appears to be very effective in virtually all patients. Maybe we have to evaluate the effect [of the combination] a little bit longer in patients with TP53 aberrations.

Reference

Ghia P, Wierda WG, Barr PM, et al. Relapse after first-line fixed duration ibrutinib + venetoclax: high response rates to ibrutinib retreatment and absence of BTK Mutations in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with up to 5 years of follow-up in the phase 2 Captivate study. Blood. 2023;142(suppl 1):633. doi:10.1182/blood-2023-187128

Recent Videos
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Experts from Sibley Memorial Hospital highlight radiation oncology technologies that have played key roles in cancer care at their institution.
Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.
Collaboration among different medical and research institutions may help improve quality of care for patients with cancer exposed to climate disasters.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.
Related Content